Overview

  • Product nameAnti-SYVN1 antibody
    See all SYVN1 primary antibodies
  • Description
    Rabbit polyclonal to SYVN1
  • Tested applicationsSuitable for: WB, IHC-P, ELISAmore details
  • Species reactivity
    Reacts with: Mouse, Human
  • Immunogen

    Synthetic peptide conjugated to KLH, from the C-terminal region of Human SYVN1 (NP_115807.1).

  • Positive control
    • Human kidney and liver tissues; T47D cell and Mouse kidney tissue lysates.

Properties

Applications

Our Abpromise guarantee covers the use of ab118483 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/100 - 1/500. Predicted molecular weight: 67 kDa.
IHC-P Use a concentration of 10 µg/ml. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
ELISA 1/1000.

Target

  • FunctionActs as an E3 ubiquitin-protein ligase which accepts ubiquitin specifically from endoplasmic reticulum-associated UBC7 E2 ligase and transfers it to substrates, promoting their degradation. Component of the endoplasmic reticulum quality control (ERQC) system also called ER-associated degradation (ERAD) involved in ubiquitin-dependent degradation of misfolded endoplasmic reticulum proteins. Also promotes the degradation of normal but naturally short-lived proteins such as SGK. Protects cells from ER stress-induced apoptosis. Protects neurons from apoptosis induced by polyglutamine-expanded huntingtin (HTT) or unfolded GPR37 by promoting their degradation. Sequesters p53/TP53 in the cytoplasm and promotes its degradation, thereby negatively regulating its biological function in transcription, cell cycle regulation and apoptosis.
  • Tissue specificityUbiquitously expressed, with highest levels in liver and kidney (at protein level). Up-regulated in synovial tissues from patients with rheumatoid arthritis (at protein level).
  • PathwayProtein modification; protein ubiquitination.
  • Sequence similaritiesBelongs to the HRD1 family.
    Contains 1 RING-type zinc finger.
  • DomainThe RING-type zinc finger is required for E3 ligase activity.
  • Post-translational
    modifications
    Not N-glycosylated.
    Auto-ubiquitinated.
  • Cellular localizationEndoplasmic reticulum membrane.
  • Information by UniProt
  • Database links
  • Alternative names
    • 1200010C09Rik antibody
    • DER3 antibody
    • E3 ubiquitin-protein ligase synoviolin antibody
    • HMG coA reductase degradation 1 homolog antibody
    • HRD1 antibody
    • KIAA1810 antibody
    • MGC40372 antibody
    • OTTHUMP00000230429 antibody
    • OTTHUMP00000230430 antibody
    • OTTHUMP00000230431 antibody
    • OTTHUMP00000230432 antibody
    • Synovial apoptosis inhibitor 1 antibody
    • Synovial apoptosis inhibitor 1, synoviolin antibody
    • Synoviolin 1 isoform b antibody
    • SYNOVIOLIN antibody
    • SYVN1 antibody
    • SYVN1_HUMAN antibody
    see all

Anti-SYVN1 antibody images

  • ab118483 at 10µg/ml staining SYVN1 in Formalin-fixed, Paraffin-embedded Human kidney tissue by Immunohistochemistry, followed by biotinylated secondary antibody, alkaline phosphatase-streptavidin and chromogen.
  • ab118483 at 10µg/ml staining SYVN1 in Formalin-fixed, Paraffin-embedded Human liver tissue by Immunohistochemistry, followed by biotinylated secondary antibody, alkaline phosphatase-streptavidin and chromogen.
  • Anti-SYVN1 antibody (ab118483) at 1/100 dilution + T47D cell lysate at 35 µg

    Predicted band size : 67 kDa
  • Anti-SYVN1 antibody (ab118483) at 1/100 dilution + Mouse kidney tissue lysate

    Predicted band size : 67 kDa

References for Anti-SYVN1 antibody (ab118483)

ab118483 has not yet been referenced specifically in any publications.

Product Wall

There are currently no Abreviews or Questions for ab118483.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"